Header Logo

Connection

Dusan Stefoski to Female

Back to Details
This is a "connection" page, showing publications Dusan Stefoski has written about Female.
Dusan Stefoski
Connection Strength
0.211
Female
  1. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
    View in: PubMed
    Score: 0.050
  2. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864.
    View in: PubMed
    Score: 0.014
  3. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117.
    View in: PubMed
    Score: 0.010
  4. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2016 Feb; 23(2):412-5.
    View in: PubMed
    Score: 0.010
  5. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol. 2014 Aug; 71(8):1025-9.
    View in: PubMed
    Score: 0.009
  6. Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis? J Clin Neurosci. 2014 Dec; 21(12):2189-93.
    View in: PubMed
    Score: 0.009
  7. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May; 13(5):472-81.
    View in: PubMed
    Score: 0.009
  8. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler. 2014 Apr; 20(4):464-70.
    View in: PubMed
    Score: 0.009
  9. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75.
    View in: PubMed
    Score: 0.008
  10. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11.
    View in: PubMed
    Score: 0.008
  11. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 Sep 06; 77(10):1020; author reply 1020.
    View in: PubMed
    Score: 0.007
  12. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology. 1991 Sep; 41(9):1344-8.
    View in: PubMed
    Score: 0.007
  13. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol. 2011 Apr; 233(1-2):147-59.
    View in: PubMed
    Score: 0.007
  14. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010 Jun; 5(2):260-5.
    View in: PubMed
    Score: 0.007
  15. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21.
    View in: PubMed
    Score: 0.007
  16. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009 Jun 25; 211(1-2):124-30.
    View in: PubMed
    Score: 0.006
  17. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3):254-60.
    View in: PubMed
    Score: 0.006
  18. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar; 8(3):244-53.
    View in: PubMed
    Score: 0.006
  19. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007 Mar 15; 109(6):2643-548.
    View in: PubMed
    Score: 0.005
  20. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003 Oct 01; 102(7):2373-8.
    View in: PubMed
    Score: 0.004
  21. Fluoroscopically guided percutaneous needle biopsy of the cervical spinal cord. AJR Am J Roentgenol. 1999 Mar; 172(3):723-5.
    View in: PubMed
    Score: 0.003
  22. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998 Nov 15; 92(10):3505-14.
    View in: PubMed
    Score: 0.003
  23. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant. 1998 Mar; 21(6):537-41.
    View in: PubMed
    Score: 0.003
  24. Myogenic and central neurogenic factors in fatigue in multiple sclerosis. Mult Scler. 1996 Feb; 1(4):236-41.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.